Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, Status and Forecast 2020-2026

Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.
Market Analysis and Insights: Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market
In 2019, the global Phosphodiesterase Type 5 (PDE5) Inhibitor market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Scope and Market Size
Phosphodiesterase Type 5 (PDE5) Inhibitor market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Phosphodiesterase Type 5 (PDE5) Inhibitor market is segmented into Sildenafil, Tadalafil, Avanafil, Vardenafil, etc.
Segment by Application, the Phosphodiesterase Type 5 (PDE5) Inhibitor market is segmented into Hospital, Retail Pharmacy, Online Pharmacies, Other, etc.
Regional and Country-level Analysis
The Phosphodiesterase Type 5 (PDE5) Inhibitor market is analysed and market size information is provided by regions (countries).
The key regions covered in the Phosphodiesterase Type 5 (PDE5) Inhibitor market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share Analysis
Phosphodiesterase Type 5 (PDE5) Inhibitor market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Phosphodiesterase Type 5 (PDE5) Inhibitor business, the date to enter into the Phosphodiesterase Type 5 (PDE5) Inhibitor market, Phosphodiesterase Type 5 (PDE5) Inhibitor product introduction, recent developments, etc.
The major vendors include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca, BaiYunShan General Factory, SK Chemicals, Teva Pharma, Dong-A ST, Metuchen Pharma, Seoul Pharma, Vectura Group, etc.

This report focuses on the global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group

Market segment by Type, the product can be split into

Sildenafil
Tadalafil
Avanafil
Vardenafil

Market segment by Application, split into

Hospital
Retail Pharmacy
Online Pharmacies
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players.
To present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Phosphodiesterase Type 5 (PDE5) Inhibitor are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.